19:31 , Jan 24, 2018 |  BC Innovations  |  Emerging Company Profile

D over L for diabetes

ImmunoMolecular Therapeutics LLC’s small molecule inhibitor of an HLA-DQ8 peptide could treat Type I diabetes without courting the broad-spectrum immunosuppression of other disease-modifying therapies in development. About 60% of Type I diabetes patients carry the...
21:34 , Aug 3, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: July 2017

New Therapeutic Targets and Biomarkers: July 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during July 2017. Therapeutic targets are defined as any protein, gene or other...
22:05 , Jul 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Lupus Mouse studies suggest inhibiting CTSS could help treat lupus. In a mouse model of the disease, CTSS levels were higher in dendritic cells from the spleen, blood and bone marrow than from the...
07:00 , Jun 29, 2015 |  BC Week In Review  |  Company News

Medivir neurology news

Medivir said it will exit the neuropathic pain therapeutic area following adverse findings in non-clinical safety studies of MIV-247. Medivir has discontinued development of the cathepsin S inhibitor and will focus on cancer and infectious...
07:00 , Apr 16, 2015 |  BC Innovations  |  Product R&D

Antagonizing psoriasis

Despite the heavy competition in psoriasis, AnaptysBio Inc. believes it can make a mark with a first-in-class antibody for a neglected, inherited form of pustular psoriasis caused by a loss-of-function mutation in the proinflammatory cytokine...
02:40 , Sep 12, 2014 |  BC Extra  |  Financial News

Virobay files for IPO

Virobay Inc. (Menlo Park, Calif.) filed to raise up to $50 million in an IPO on NASDAQ underwritten by Piper Jaffray; JMP Securities; Cantor Fitzgerald; and Summer Street Research Partners. Virobay has completed Phase I...
07:00 , Sep 4, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Cathepsin S Studies in patient samples and mice suggest inhibiting cathepsin S could help prevent cancer metastasis to the brain. In tissue samples from...
07:00 , Sep 1, 2014 |  BioCentury  |  Finance

Nurturing killer seeds

Index Ventures is not the first VC to operate an incubator that conducts killer experiments on seed projects. But what could set the "Index Nursery" apart is the firm's intention to publicize its failures along...
07:00 , Jun 3, 2013 |  BC Week In Review  |  Clinical News

VBY-036: Phase I started

Virobay began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate escalating doses of oral VBY-036 in 48 healthy volunteers. Virobay Inc. , Menlo Park, Calif.   Product: VBY-036   Business: Neurology   Molecular target:...
07:00 , Mar 25, 2013 |  BC Week In Review  |  Clinical News

VBY-891: Phase I started

Virobay began a double-blind, placebo-controlled, dose-escalation Phase I trial to evaluate single and multiple doses of oral VBY-891 in about 90 healthy volunteers. The trial start triggered an undisclosed payment to Virobay from Leo Pharma...